NASDAQ:OBSV

ObsEva News Headlines

$2.52
-0.07 (-2.70 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.49
$2.60
50-Day Range
$2.47
$3.19
52-Week Range
$1.86
$5.55
Volume1.61 million shs
Average Volume4.10 million shs
Market Capitalization$145.03 million
P/E RatioN/A
Dividend YieldN/A
Beta0.76

ObsEva (NASDAQ OBSV) News Headlines Today

SourceHeadline
ObsEva SA (NASDAQ:OBSV) Short Interest UpdateObsEva SA (NASDAQ:OBSV) Short Interest Update
americanbankingnews.com - July 31 at 7:30 PM
FY2024 Earnings Forecast for ObsEva SA Issued By Wedbush (NASDAQ:OBSV)FY2024 Earnings Forecast for ObsEva SA Issued By Wedbush (NASDAQ:OBSV)
americanbankingnews.com - July 30 at 9:42 AM
ObsEva (NASDAQ:OBSV) Given Buy Rating at WedbushObsEva (NASDAQ:OBSV) Given Buy Rating at Wedbush
americanbankingnews.com - July 28 at 12:56 PM
The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts - BenzingaThe Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts - Benzinga
benzinga.com - July 28 at 7:41 AM
Mid-Morning Market Update: Markets Open Lower; General Electric Earnings Beat Views - BenzingaMid-Morning Market Update: Markets Open Lower; General Electric Earnings Beat Views - Benzinga
benzinga.com - July 27 at 2:52 PM
Stock Traders Buy Large Volume of ObsEva Call Options (NASDAQ:OBSV)Stock Traders Buy Large Volume of ObsEva Call Options (NASDAQ:OBSV)
americanbankingnews.com - July 27 at 11:54 AM
Pre-Open Stock Movers 07/27: (OGEN) (OBSV) (FFIV) Higher; (BTBT) (MINM) (UPS) Lower (more...) - StreetInsider.comPre-Open Stock Movers 07/27: (OGEN) (OBSV) (FFIV) Higher; (BTBT) (MINM) (UPS) Lower (more...) - StreetInsider.com
streetinsider.com - July 27 at 9:52 AM
34 Stocks Moving in Tuesdays Pre-Market Session Gainers Eyegate Pharmaceuticals Inc - Benzinga34 Stocks Moving in Tuesday's Pre-Market Session Gainers Eyegate Pharmaceuticals Inc - Benzinga
benzinga.com - July 27 at 9:52 AM
Organon Stock Slides Despite Hookup with ObsEva - Baystreet.caOrganon Stock Slides Despite Hookup with ObsEva - Baystreet.ca
baystreet.ca - July 27 at 9:52 AM
Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor - Business WireOrganon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigational Agent Being Evaluated as a First-in-Class Treatment for Preterm Labor - Business Wire
businesswire.com - July 27 at 9:52 AM
ObsEva SA (NASDAQ:OBSV) Expected to Announce Earnings of -$0.26 Per ShareObsEva SA (NASDAQ:OBSV) Expected to Announce Earnings of -$0.26 Per Share
americanbankingnews.com - July 19 at 11:34 AM
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock? - Yahoo FinanceIs the Options Market Predicting a Spike in ObsEva (OBSV) Stock? - Yahoo Finance
finance.yahoo.com - July 12 at 2:29 PM
Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?Is the Options Market Predicting a Spike in ObsEva (OBSV) Stock?
finance.yahoo.com - July 12 at 2:29 PM
ObsEva to Present Ebopiprant (OBE022) Data at the Society - GlobeNewswireObsEva to Present Ebopiprant (OBE022) Data at the Society - GlobeNewswire
globenewswire.com - July 2 at 1:26 PM
ObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting - Yahoo FinanceObsEva to Present Ebopiprant (OBE022) Data at the Society for Reproductive Investigation 68th Annual Meeting - Yahoo Finance
finance.yahoo.com - July 2 at 8:26 AM
ObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty - GlobeNewswireObsEva Presents Clinical Data on Open-Label Pilot Study of Yselty - GlobeNewswire
globenewswire.com - June 30 at 8:45 AM
ObsEva To Present Data on Two Clinical Development Programs - GlobeNewswireObsEva To Present Data on Two Clinical Development Programs - GlobeNewswire
globenewswire.com - June 24 at 9:48 AM
Do Hedge Funds Love ObsEva SA (OBSV)? - Yahoo FinanceDo Hedge Funds Love ObsEva SA (OBSV)? - Yahoo Finance
finance.yahoo.com - June 15 at 12:19 AM
Do Hedge Funds Love ObsEva SA (OBSV)?Do Hedge Funds Love ObsEva SA (OBSV)?
finance.yahoo.com - June 14 at 7:18 PM
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on - GlobeNewswireObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on - GlobeNewswire
globenewswire.com - June 10 at 1:10 AM
ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
finance.yahoo.com - June 10 at 1:10 AM
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 - Yahoo FinanceObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021 - Yahoo Finance
finance.yahoo.com - June 2 at 7:51 AM
ObsEva SA Announces that Shareholders Approved all Board - GlobeNewswireObsEva SA Announces that Shareholders Approved all Board - GlobeNewswire
globenewswire.com - May 31 at 9:59 AM
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2021 Annual General Meeting held on May 28, 2021
benzinga.com - May 31 at 1:16 AM
ObsEva Announces Proposed Changes to the Composition of its - GlobeNewswireObsEva Announces Proposed Changes to the Composition of its - GlobeNewswire
globenewswire.com - May 25 at 9:00 PM
ObsEva Announces Proposed Changes to the Composition of its Board of DirectorsObsEva Announces Proposed Changes to the Composition of its Board of Directors
finance.yahoo.com - May 25 at 9:00 PM
OBSV Stock: The Big Clinical Trial News Boosting ObsEva Today - InvestorPlaceOBSV Stock: The Big Clinical Trial News Boosting ObsEva Today - InvestorPlace
investorplace.com - May 23 at 12:53 AM
ObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study - Yahoo FinanceObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study - Yahoo Finance
finance.yahoo.com - May 22 at 9:51 AM
ObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study - BenzingaObsEva Shares Gains On Positive Linzagolix Data In Uterine Fibroids Study - Benzinga
benzinga.com - May 20 at 8:21 AM
Newron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA - Yahoo Finance UKNewron announces Paragraph IV ANDA filings for Xadago(R) (safinamide) in the USA - Yahoo Finance UK
uk.finance.yahoo.com - May 20 at 3:21 AM
ObsEva Announces Final Results from the Phase 3 PRIMROSE - GlobeNewswireObsEva Announces Final Results from the Phase 3 PRIMROSE - GlobeNewswire
globenewswire.com - May 20 at 3:21 AM
What Kind Of Shareholders Hold The Majority In ObsEva SAs (NASDAQ:OBSV) Shares? - Yahoo FinanceWhat Kind Of Shareholders Hold The Majority In ObsEva SA's (NASDAQ:OBSV) Shares? - Yahoo Finance
finance.yahoo.com - May 17 at 5:34 PM
What Kind Of Shareholders Hold The Majority In ObsEva SAs (NASDAQ:OBSV) Shares?What Kind Of Shareholders Hold The Majority In ObsEva SA's (NASDAQ:OBSV) Shares?
finance.yahoo.com - May 17 at 5:34 PM
Pharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer - StreetInsider.comPharvaris Appoints Wim Souverijns, Ph.D., as Chief Community Engagement & Commercial Officer - StreetInsider.com
streetinsider.com - May 12 at 10:24 AM
ObsEva Announces First Quarter 2021 Financial Results and - GlobeNewswireObsEva Announces First Quarter 2021 Financial Results and - GlobeNewswire
globenewswire.com - May 6 at 3:04 AM
ObsEva appoints Clive Bertram as Chief Commercial Officer - GlobeNewswireObsEva appoints Clive Bertram as Chief Commercial Officer - GlobeNewswire
globenewswire.com - May 6 at 3:04 AM
ObsEva SA (OBSV) Reports Complete Enrollment of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - StreetInsider.comObsEva SA (OBSV) Reports Complete Enrollment of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - StreetInsider.com
streetinsider.com - May 4 at 8:35 AM
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - GlobeNewswireObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain - GlobeNewswire
globenewswire.com - May 4 at 8:35 AM
ObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated PainObsEva Announces Enrollment Completion of Linzagolix Phase 3 EDELWEISS 3 Trial for Patients with Moderate to Severe Endometriosis-Associated Pain
finance.yahoo.com - May 4 at 8:35 AM
FinLab AG: Falk Schäfers and Matthias Kröner appointed to the Executive Board - Yahoo Finance UKFinLab AG: Falk Schäfers and Matthias Kröner appointed to the Executive Board - Yahoo Finance UK
uk.finance.yahoo.com - April 30 at 11:41 PM
ObsEva SA presents posters at the ACOG Annual Clinical and - GlobeNewswireObsEva SA presents posters at the ACOG Annual Clinical and - GlobeNewswire
globenewswire.com - April 30 at 6:40 PM
ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021ObsEva SA presents posters at the ACOG Annual Clinical and Scientific Virtual Meeting April 30 - May 2, 2021
finance.yahoo.com - April 30 at 6:40 PM
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout - BenzingaThe Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout - Benzinga
benzinga.com - April 28 at 12:58 AM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Yahoo FinanceObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Yahoo Finance
finance.yahoo.com - April 27 at 2:58 PM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty TreatmentObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment
finance.yahoo.com - April 27 at 2:58 PM
ObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - BenzingaObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty Treatment - Benzinga
benzinga.com - April 27 at 9:57 AM
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants - GlobeNewswireObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants - GlobeNewswire
globenewswire.com - April 27 at 9:57 AM
ObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial ParticipantsObsEva Initiates PRIMROSE 3 Bone Mineral Density Follow-Up Study in PRIMROSE 1 and PRIMROSE 2 Trial Participants
finance.yahoo.com - April 27 at 9:56 AM
ObsEva Annual General Meeting 2021 Nasdaq:OBSV - GlobeNewswireObsEva Annual General Meeting 2021 Nasdaq:OBSV - GlobeNewswire
globenewswire.com - April 22 at 8:57 AM
ObsEva readies $50M worth common stock offering - Seeking AlphaObsEva readies $50M worth common stock offering - Seeking Alpha
seekingalpha.com - March 9 at 2:44 PM
This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.